TECVAYLI®
(teclistamab-cqyv)
Medical inquiries
This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
TECVAYLI® (teclistamab-cqyv)
Medical Information
TECVAYLI - Sites of Administration
Last Updated: 08/22/2024
Abbreviations: CRS, cytokine release syndrome; ICANS, immune effector cell-associated neurotoxicity.
a
product labeling
- Janssen cannot recommend any practices, procedures, or dosing modifications that deviate from product labeling and are not approved by the regulatory agencies.
- TECVAYLI is for subcutaneous injection only.1
- TECVAYLI should be administered by a healthcare provider with adequate medical personnel and appropriate medical equipment to manage severe reactions, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).1
- Inject the required volume of TECVAYLI into the subcutaneous tissue of the abdomen (preferred injection site). Alternatively, TECVAYLI may be injected into the subcutaneous tissue at other sites (eg, thigh). If multiple injections are required, TECVAYLI injections should be at least 2 cm apart.1
- Do not inject into tattoos or scars or areas where the skin is red, bruised, tender, hard or not intact.1
Literature Search
A literature search of MEDLINE®
References
| 1 | TECVAYLI (teclistamab-cqyv) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.;https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TECVAYLI-pi.pdf. |